China has applied to patent a drug candidate being developed by US biotechnology firm Gilead Sciences in its search for a cure for coronavirus infection. It could raise questions on intellectual property and marketing rights.
Who owns the coronavirus cure? China’s move to patent Gilead’s experimental drug for the novel virus could lead to legal wrangle
Posted in biotech/medical, law